The efficacy is less encouraging, until recently, a significant clinical response with lower toxicities has been elicited in a patient with highly aggressive recurrent multifocal glioblastoma multiforme (GBM) who received both intracavitary and intraventricular administration of the interleukin-13 receptor alpha2 (IL13Rα2)-directed BBζ CAR-T cells (Brown et al., 2016), highlighting that CAR-T cell therapy could be useful for treating solid tumors by continuous optimization. This evidence concerns the gene IL13RA2 and glioblastoma.